Thymidylate synthase, thymidine phosphorylase, VEGF and p53 protein expression in primary colorectal cancer for predicting response to 5-fluorouracil-based chemotherapy
- PMID: 19956517
- PMCID: PMC2785918
- DOI: 10.4143/crt.2005.37.4.216
Thymidylate synthase, thymidine phosphorylase, VEGF and p53 protein expression in primary colorectal cancer for predicting response to 5-fluorouracil-based chemotherapy
Abstract
Purpose: In the treatment of advanced metastatic colorectal cancer, several new agents, such as irinotecan and oxaliplatin, have been developed, which have improved both disease free and overall survivals. Among these agents, 5-fluorouracil (5-FU) still remains one of the most active agents, and the selection of patients who can benefit from 5-FU-based chemotherapy is still important, as those unlikely to benefit could be spared the harmful side effects. The expression levels of thymidylate synthase (TS), thymidine phosphorylase (TP) and p53 have been known to be associated with the clinical response to 5-FU-based therapy as well as the prognosis, and that of vascular endothelial growth factor (VEGF) is associated with poor survival.
Materials and methods: The relationship between the expressions of TS, TP, VEGF and p53 in primary tumors, using immunohistochemistry, and the response of 45 metastatic colorectal cancer patients (M:F=25:20, median age 59 yrs) to 5-FU-based chemotherapy were evaluated.
Results: Thirty-seven patients were treated with 5-FU/LV/irinotecan (FOLFIRI) and 8 with 5-FU/LV/oxaplatin (FOLFOX). The overall response rate was 28.9% (13/45). When immunohistochemically analyzed with monoclonal antibodies against TS, TP, VEGF and p53, 55.6% of the patients (25/45) were positive for TS, 48.9% (22/45) for TP, 82.2% (37/45) for VEGF, and 80% (36/45) for p53. There was a significant difference in the intensity of TS expression between the clinical responders and non-responders (p=0.036). In terms of the staining pattern of TS expression, diffuse staining was correlated with a poor response (p=0.012) and poor survival (p=0.045). However, there was no correlation between the expressions of TP, VEGF or P53 and the response to chemotherapy.
Conclusion: These results suggest that the expression of TS in primary colorectal cancer might be an important prognostic factor for chemotherapy response and survival, and might be a useful therapeutic marker for the response of chemotherapy.
Keywords: Fluorouracil; Metastatic colorectal cancer; Thymidine phosphorylase; Thymidylate synthase; Vascular endothelial growth factor A; p53.
Figures


Similar articles
-
Predictive role of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer patients receiving adjuvant 5-fluorouracil.Oncology. 2006;70(5):366-77. doi: 10.1159/000098110. Epub 2006 Dec 15. Oncology. 2006. PMID: 17179731
-
Prognostic role of thymidylate synthase, thymidine phosphorylase/platelet-derived endothelial cell growth factor, and proliferation markers in colorectal cancer.Clin Cancer Res. 2000 Mar;6(3):1063-72. Clin Cancer Res. 2000. PMID: 10741735
-
Thymidylate synthase, dihydropyrimidine dehydrogenase, ERCC1, and thymidine phosphorylase gene expression in primary and metastatic gastrointestinal adenocarcinoma tissue in patients treated on a phase I trial of oxaliplatin and capecitabine.BMC Cancer. 2008 Dec 23;8:386. doi: 10.1186/1471-2407-8-386. BMC Cancer. 2008. PMID: 19105824 Free PMC article. Clinical Trial.
-
Integration of novel agents in the treatment of colorectal cancer.Cancer Chemother Pharmacol. 2004 Sep;54 Suppl 1:S32-9. doi: 10.1007/s00280-004-0884-0. Cancer Chemother Pharmacol. 2004. PMID: 15309512 Review.
-
Novel aspects of resistance to drugs targeted to dihydrofolate reductase and thymidylate synthase.Biochim Biophys Acta. 2002 Jul 18;1587(2-3):164-73. doi: 10.1016/s0925-4439(02)00079-0. Biochim Biophys Acta. 2002. PMID: 12084458 Review.
Cited by
-
Immunoexpression of TS, p53, COX2, EGFR, MSH6 and MLH1 biomarkers and its correlation with degree of differentiation, tumor staging and prognostic factors in colorectal adenocarcinoma: a retrospective longitudinal study.Sao Paulo Med J. 2019 May 8;137(1):33-38. doi: 10.1590/1516-3180.2018.0270071218. Sao Paulo Med J. 2019. PMID: 31116268 Free PMC article.
-
Epigenetic Approaches to Overcome Fluoropyrimidines Resistance in Solid Tumors.Cancers (Basel). 2022 Jan 29;14(3):695. doi: 10.3390/cancers14030695. Cancers (Basel). 2022. PMID: 35158962 Free PMC article. Review.
-
Comparison of thymidine phosphorylase expression and prognostic factors in gallbladder and bile duct cancer.BMC Cancer. 2010 Oct 19;10:564. doi: 10.1186/1471-2407-10-564. BMC Cancer. 2010. PMID: 20955617 Free PMC article.
-
Does anti-p53 antibody status predict for clinical outcomes in metastatic colorectal cancer patients treated with fluoropyrimidine, oxaliplatin, plus bevacizumab as first-line chemotherapy?BMC Cancer. 2015 Oct 21;15:760. doi: 10.1186/s12885-015-1751-6. BMC Cancer. 2015. PMID: 26490659 Free PMC article.
-
Thymidine phosphorylase expression and prognosis in colorectal cancer treated with 5-fluorouracil-based chemotherapy: A meta-analysis.Mol Clin Oncol. 2017 Dec;7(6):943-952. doi: 10.3892/mco.2017.1436. Epub 2017 Oct 3. Mol Clin Oncol. 2017. PMID: 29285354 Free PMC article.
References
-
- Johnston PG, Allegra CJ. Colorectal cancer biology: clinical implications. Semin Oncol. 1995;22:418–432. - PubMed
-
- Grem JL. Fluorinated pyrimidines. In: Chabner BA, Collins JM, editors. Cancer chemotherapy, principles and practice. Philadelphia, PA: Lippincott; 1990. pp. 180–224.
-
- Moertel CG. Chemotherapy for colorectal cancer. N Engl J Med. 1994;330:1136–1142. - PubMed
-
- Sotos GA, Grogan L, Allegra CJ. Preclinical and clinical aspects of biomodulation of 5-fluorouracil. Cancer Treat Rev. 1994;20:11–49. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous